Literature DB >> 26712194

Rare primary fallopian tube carcinoma; a gynaecologist's dilemma.

Shama Chaudhry1, Rubina Hussain1, Madiha Munir Zuberi2, Zehra Zaidi2.   

Abstract

Primary fallopian tube carcinoma is rare and accounts for 0.14-1.8% of all malignancies of the female genital tract. It has been found to be associated with nulliparity and subfertility, as well as with pelvic inflammatory disease. High parity has been reported to be protective but not in our 3 cases. History of pregnancy and the use of oral contraceptives decrease the PFTC risk significantly in literature. PFTC has been described in high-risk breast-ovarian cancer families with germ-line BRCA-1 and BRCA-2 mutations. Symptoms are nonspecific and include abdominal pelvic pain, vaginal bleeding and watery discharge. However, diagnosis is rarely achieved pre-operative because of misleading imaging. In many cases, the diagnosis is made incidentally on histopathology after surgery for an un-related condition commonly being an ovarian carcinoma.

Entities:  

Keywords:  PFTC (Primary fallopian tube carcinoma), CA-125 levels, EOC (Epithelial ovarian cancer), BRCA-1 and BRCA-2 mutations.

Mesh:

Substances:

Year:  2016        PMID: 26712194

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  3 in total

1.  Case report: Unpredictable nature of tubal cancer.

Authors:  Sigit Purbadi; Victor Prana Andika Santawi; Hartono Tjahjadi; Sahat Matondang; Laila Nuranna
Journal:  Ann Med Surg (Lond)       Date:  2020-01-16

2.  Primary Fallopian Tube Carcinoma: A Case Report and Literature Review.

Authors:  Meral Rexhepi; Elizabeta Trajkovska; Hysni Ismaili; Florin Besimi; Nagip Rufati
Journal:  Open Access Maced J Med Sci       Date:  2017-05-20

3.  Fallopian tube serous adenocarcinoma with dizziness as the initial symptom: a case report.

Authors:  Yuyao Wang; Yang Bian; Feng Qiu; Pu Fang
Journal:  J Int Med Res       Date:  2019-09-10       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.